UNSPSC 51101924: Bulaquine

This classification denotes an antimalarial agent with the molecular formula C21H27N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TSQ6U39Q3G, chemically known as 2(3h)-furanone, dihydro-3-(1-((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)ethylidene)- but generally known as bulaquine, which bears US NIH Compound Identifier 3036820. European Medicines Agency schedules Bulaquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00894MIG. The term BULAQUINE is an International Non-Proprietary Name.

Most nations schedule bulaquine under HS 29349990 and SITC 51579. As of Q4 2014, BULAQUINE remains the US FDA Preferred Term for this commodity. Bulaquine bears US NLM identifiers UMLS ID C0082079 and NCI Concept Code C75997. SMILES: O1CC/C(=C(\NCCCC(NC2C3NCCCC3CC(OC)C2)C)C)C1=O.

UNSPSC 51101924 Bulaquine, a Commodity code, covers pharmaceutical products procured by state and local health agencies, though recent state and local opportunities under this code show limited direct activity. The two most recent records are a completed Illinois Department of Public Health award through the MMCAP Infuse consortium to Chartwell Rx LLC for antibiotic pharmaceuticals (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets) valued at $2,999,999.11 over the three-year contract term, and a Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems procurement. State and local health departments are the primary issuing bodies under this code, procuring pharmaceutical inventory for emergency response, disease control, and community health initiatives through competitive bidding processes and cooperative purchasing consortia. Contracts typically span 12 months with renewal options, require quarterly or regular deliveries to designated health facilities, and include standard compliance requirements such as drug-free workplace certification and E-Verify authorization.

Recent procurement activity appears concentrated in Florida and Illinois. The Illinois Department of Public Health's MMCAP Infuse piggyback award demonstrates the use of cooperative purchasing vehicles to secure pharmaceutical supply at scale, while Seminole County's procurement reflects county-level health system demand for emergency pharmaceutical inventory. Neither opportunity carried explicit set-aside designations for disadvantaged business enterprises. Response deadlines for current opportunities have passed (the Seminole County IFB closed July 26, 2023), and no open solicitations under this code are currently available. The code shows moderate recent activity but limited current pipeline visibility for pursuing new opportunities.